PMID: 11926439Apr 3, 2002Paper

Economic impact and formulary positioning of linezolid: a new anti-Gram-positive antimicrobial

The Journal of Hospital Infection
D Nathwani

Abstract

Gram-positive bacteria have emerged as major causes of colonization and serious infection within the nosocomial and increasingly also within the community setting. These infections have significantly contributed to patient morbidity and mortality as well as prolongation of hospital stay, a key determinant of the cost of an episode of infection in hospital. In many countries globally, infections due to methicillin-resistant Staphylococcus aureus (MRSA) are providing the greatest burden of clinical infection, often occurring in vulnerable patients or "high risk" therapeutic settings. Combined with this scenario is the increasing requirement for health care organizations to provide cost-effective health care as well as care that is delivered on evidence-based practice delivered through formularies or guidelines. This article aims to: 1) summarize the key economic considerations pertinent to these multiresistant infections but with an emphasis on MRSA, 2) discuss the current therapeutic options of managing MRSA infections, and 3) discuss the formulary positioning of linezolid by means of outlining its core strengths, weaknesses and the opportunity it provides to hospital infection management.

References

Aug 1, 1996·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·W R Jarvis
Feb 1, 1997·The Journal of Antimicrobial Chemotherapy·A C BoyterD Nathwani
Apr 1, 1997·The Journal of Antimicrobial Chemotherapy·D NathwaniP Davey
Aug 11, 1997·Archives of Internal Medicine·G L FraserB S Prato
May 13, 1998·The Journal of Antimicrobial Chemotherapy·M Rahman
May 23, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R C Moellering
Nov 20, 1998·The Journal of Infection·P Davey, D Nathwani
Mar 19, 1999·Emerging Infectious Diseases·R J RubinA Moiduddin
Jan 9, 1992·PharmacoEconomics·S E Parker, P G Davey
Dec 9, 1993·PharmacoEconomics·P Jewesson
Jul 10, 1999·Archives of Internal Medicine·A G JensenN Frimodt-Møller
Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C GonzálezJ J Picazo
Nov 24, 1999·JAMA : the Journal of the American Medical Association·C ChaixC Brun-Buisson
Sep 15, 2000·The Medical Letter on Drugs and Therapeutics
Oct 6, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J E McGowan
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E RubinsteinUNKNOWN Linezolid Nosocomial Pneumonia Study Group

❮ Previous
Next ❯

Citations

Mar 2, 2005·International Journal of Antimicrobial Agents·Dilip Nathwani
Oct 12, 2007·Expert Opinion on Pharmacotherapy·Hisham Ziglam
Apr 2, 2008·Expert Opinion on Pharmacotherapy·Santiago Grau, Carlos Rubio-Terrés
Oct 16, 2004·Expert Review of Anti-infective Therapy·Hisham Ziglam, Dillip Nathwani
Jun 16, 2005·Expert Review of Anti-infective Therapy·Matteo BassettiDante Bassetti
Jun 11, 2005·The Journal of Antimicrobial Chemotherapy·H M ZiglamD Nathwani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.